Parakkal Deepak, Wooseob Kim, Michael A Paley, Monica Yang, Alexander B Carvidi, Emanuel G Demissie, Alia A El-Qunni, Alem Haile, Katherine Huang, Baylee Kinnett, Mariel J Liebeskind, Zhuoming Liu, Lily E McMorrow, Diana Paez, Niti Pawar, Dana C Perantie, Rebecca E Schriefer, Shannon E Sides, Mahima Thapa, Maté Gergely, Suha Abushamma, Sewuese Akuse, Michael Klebert, Lynne Mitchell, Darren Nix, Jonathan Graf, Kimberly E Taylor, Salim Chahin, Matthew A Ciorba, Patricia Katz, Mehrdad Matloubian, Jane A O'Halloran, Rachel M Presti, Gregory F Wu, Sean P J Whelan, William J Buchser, Lianne S Gensler, Mary C Nakamura, Ali H Ellebedy, Alfred H J Kim
BACKGROUND: Patients with chronic inflammatory disease (CID) treated with immunosuppressive medications have increased risk for severe COVID-19. Although mRNA-based SARS-CoV-2 vaccination provides protection in immunocompetent persons, immunogenicity in immunosuppressed patients with CID is unclear. OBJECTIVE: To determine the immunogenicity of mRNA-based SARS-CoV-2 vaccines in patients with CID. DESIGN: Prospective observational cohort study...
November 2021: Annals of Internal Medicine